The National Alliance of Advocates
for Buprenorphine Treatment

Buprenorphine (Suboxone®, Subutex®3, Zubsolv®4, Bunavail™5, Probuphine®6) is an opioid medication used to treat opioid addiction in the privacy of a physician's office.1 Buprenorphine can be dispensed for take-home use, by prescription.1 This, in addition to the pharmacological and safety profile of buprenorphine, makes it an attractive treatment for patients addicted to opioids.2


naabt sealWe welcome all donations. We have 501c(3) tax exempt status with the IRS as a charitable organization. Donations are tax deductible in the year which the donation was made.

Paypal, credit cards

Donation Options

There are three options for making donations. The first is a recurring donation/subscription which can be made in any amount on a weekly, monthly or yearly basis. The second option is to make a one-time donation of any amount by clicking the "Paypal Donate" button below. The third is by mail.

501(c)3 IRS Determination letter

1. Make a recurring donation:

Donation amount:
Frequency of donation: Weekly


2. One-time donation:


3. Mail donation:

P.O.Box 333
Farmington, CT 06034


Your contribution will be used for:

  • The continuing education and dissemination of information concerning opioid addiction treatment
  • Our mission to reduce the stigma and help connect patient to physician.

See about us for more details:


The Purpose of Buprenorphine Treatment:

To suppress the debilitating symptoms of cravings and withdrawal, enabling the patient to engage in therapy, counseling and support, so they can implement positive long-term changes in their lives which develops into the new healthy patterns of behavior necessary to achieve sustained addiction remission. - explain -

The National Alliance of Advocates for Buprenorphine Treatment is a non-profit organization charged with the mission to:

  1. U.S. Food and Drug Administration, FDA Talk Paper, T0238, October 8, 2002, Subutex and Suboxone approved to treat opiate dependence.
  2. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, Md: Substance Abuse and Mental Health Services Administration, 2004.
  3. Subutex Discontinued in the US market in late 2011.
  4. Zubsolv (bup/nx sublingual tablet) FDA approved 7/3/2013 see buprenorphine pipeline graphic -in pharmacies now.
  5. Bunavail (bup/nx bucal film) FDA approved 6/6/2014 see buprenorphine pipeline graphic -in pharmacies now.
  6. Probuphine FDA approved 5/26/2016 - FDA Probuphine press release